Emlenoflast

DB18304InvestigationalSmall molecule

Emlenoflast: Overview.

Mechanism: Pharmacologically active on NACHT, LRR and PYD domains-containing protein 3
Curator reviewed
Formula / weight: C₁₉H₂₄N₄O₃S · 388.49 g/mol (avg)
Also known as: 1h-pyrazole-3-sulfonamide, n-(((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino)carbonyl)-1-(1-methylethyl)- · Inzomelid · N-[[(1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL) AMINO]CARBONYL]-1-(1-METHYLETHYL)-1H-PYRAZOLE-3-SULFONAMIDE
Code names: IZD-174 · MCC-7840

Resolves to

Compound

Structure

InChIKeyMTOUOUSKXWSTAX-UHFFFAOYSA-NSMILESCC(C)N1C=CC(=N1)S(=O)(=O)NC(=O)NC1=C2CCCC2=CC2=C1CCC2

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Emlenoflast, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.